Yinghong Gao has extensive drug discovery, biotech investment and business development experience. She has been involved in the post investment management of over 10 Viva portfolio companies such as DTx (acquired by Novartis), Nerio (acquired by BI), and AmacaThera (partnered with Pacira). She has contributed to the discovery of Neurocrine's GnRH antagonist ORILISSA® for endometriosis and Arena's S1P receptor modulator Etrasimod (VELSIPITY®) for ulcerative colitis.

Bu Yin is a patent attorney with 14 years of experience in developing IP portfolios and providing strategic counseling in areas including biologics (e.g., antibody, RNA, cell, and gene therapies), diagnostics, and biotech tools. Bu has extensive experience supporting patent dispute resolution and cross-border transactions, including company-side and investor-side IP due-diligence.

Vanessa has spent her academic and business career exclusively in life sciences and healthcare. She has worked at large pharmaceutical, biotechnology, and technology companies such as Sanofi, Abbott, and NVIDIA, as well as start-ups including Ingenuity Systems and Fabric Genomics. Vanessa is currently a Senior Director at Eli Lilly, where she focuses on the Lilly TuneLab AI/ML Drug Discovery Platform. She began her career in academia and clinical research at UC Berkeley and UCSF studying molecular and cell biology, and later transitioned into roles focused on building and launching new products.

Yue obtained her Bachelor's degree from Fudan University and continued her research at Yale University. Yue joined the Jorgensen lab where she worked on methodology development of the free energy perturbation calculation. After graduation, Yue worked as a computational chemist at the Broad Institute of MIT and Harvard and were actively involved in multiple novel drug discovery projects. Yue is now leading the computational chemistry group at Viva and is responsible to various drug discovery projects and methodology development endeavor.

Dr. Bryan Fuchs has more than 20 years of drug discovery experience across multiple therapeutic areas, including gastroenterology, fibrosis, inflammation, and oncology. He is currently the Head of Ferring Ventures San Diego, which is developing a novel pipeline of targeted radionuclide therapies. He also serves as a Board Member of the Peptide Therapeutics Foundation.

Dr. Susan L. Chen has 20+ years of experience in the peptide and small molecule CRO and CDMO industries. She has rich experience in pharmaceutical drug development, from early phase to late phase, and from research to commercialization, including PRD/ARD, GMP manufacturing, pre-clinical work, clinical development (Phase I–III), operations, regulatory, safety, and commercialization. She has held key positions at several renowned CDMO companies, e.g., AmbioPharm, Sinopep, WuXi STA, and ChemPartner. She earned her Ph.D. degree in Organic Chemistry and Chemical Engineering from the National University of Singapore.

Ph.D. from UT Southwestern Medical Center, Frank and Sara McKnight fellow
Helen Hay Whitney fellow, Harvard Medical School
Scientific Leader & GSK Fellow, GlaxoSmithKline
Senior Director, Johnson & Johsnon

Aiden Aceves is a Principal at Insight Partners, where he invests in therapeutics, pharma services and life sciences software. Prior to becoming an investor, Aiden worked on founding and operating biotechnology and machine learning companies in San Diego California, where he is based.

Aiden traces his academic lineage to Caltech, where he earned his doctorate in the lab of Dr. Steven Mayo, a leader in the space of computational protein engineering. Aiden received his B.S. in synthetic chemistry from the University of California, Riverside.

Alex holds a PhD in Neuroscience from Hopkins and completed her postdoc in the Doudna lab at UCB. She has spent six years in biotech BD and program selection, four of them within the BridgeBio ecosystem. She currently leads BD efforts at GondolaBio, focused on identifying therapeutics for Mendelian diseases.

Anthony is a biotech investor and operator who has spent over a decade at well known biotech investment firms including RA Capital, Mission BioCapital, and Lyfe Capital. He led or co-led investments in Tidal Therapeutics (acquired by Sanofi for $160M upfront + $310M in milestones) and Vedere Bio (acquired by Novartis for $150M upfront + $130M in milestones), and backed companies such as QurAlis, ShapeTx, Mediar Therapeutics, Dren Bio, and Tune Therapeutics—advancing programs in neurodegeneration, RNA editing, and oncology. Anthony holds a B.A. in Biochemistry from Trinity College Dublin and a D.Phil in Biophysics from Oxford University, where his research focused on the biological applications of DNA cages for targeted macromolecule delivery.

Dr. Liu is the CSO of Full-Life Technologies. Prior to that, he was CEO of Focus-X Therapeutics (acquired 2022), the Head of Chemistry of Novo Nordisk US, and Calibrium LLC (acquired 2015), and was a Group Leader at Eli Lilly. Dr. Liu received his Ph.D. from Shanghai Institute of Organic Chemistry.

After receiving her Ph.D. in Neuropharmacology, Fei's industrial career began in 2007 at Theravance as an in vivo pharmacologist and led a lab in driving multiple research projects from exploratory, lead optimization to DC nomination and IND filing. Joining Boehringer Ingelheim in 2015, she has steadily taken on roles of increasing responsibility in Research. During the 13-year she spent in the R&D organizations, Fei and her team have contributed to two approved products and many assets in the clinical pipeline ranging from Ph1 to Ph3. In 2020, she joined the Boehringer Ingelheim Venture Fund USA as an Investment Director and took over the Managing Director role in 2021 to lead the US Operations. Fei has served/is serving Board role in ProTgen, Rgenta Therapeutics, ArrePath, xCures, STRM. Bio, Libra and Abexxa Biologics.

Josh Xiao is a co-founder of a stealth NewCo. Previously Josh served as an EIR at RA Ventures, the NewCo incubator of RA Capital, Vice President of Research at two startups and Antibody drug discovery lead for Oncology at Amgen, after his postdoctoral training at Columbia University.